Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?

Key Takeaways LLY shares fell 5.9% after an HSBC downgrade citing U.S. pricing pressure and rising obesity-drug competition.HSBC warned that pricing pressure and affordability push could reshape competition in the obesity drug market.Continued availability of compounded tirzepatide in the U.S. could divert demand from LLY's branded drugs.Eli Lilly (LLY) remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster tirzepatide (GLP-1) injections, Mounjaro for ...